This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Introduction
Patellar tendinopathy (PT), also known as jumper's knee, is an activity-dependant chronic condition characterised by anterior pain to the knee 1 . Injuries to the patellar tendon are common 2, 3 . They account for nearly 30% of knee injuries in US high school athletes 4 and are prevalent amongst volleyball (45%) and basketball (32%) players alike 1 . PT is also found in military cohorts and the injury can lead to prolonged periods of disability 5 . Both tendon neovascularisation and thickening are associated with PT injuries 6, 7 . Furthermore, some authors report the injury to associate with an increase in collagen type III fibres along with elevated levels of glycosaminoglycans 8 . A number of risk factors for PT have been tentatively reported in the literature such as increased weight and BMI 9 and there is a growing body of evidence to suggest that genetics can play a role in the predisposition to human tendinopathy 9, 10 . However, to date, and to our knowledge, no single study has investigated the role of human DNA methylation (as an epigenetic factor) in sports injury phenotypes like PT.
DNA methylation occurs when a methyl group binds to a cytosine nucleotide base converting it to 5-methylcytosine 11 . This takes place predominantly in CpG rich regions (CpG islands) which are typically located in the promoter regions of genes. DNA methylation tends to down regulate gene expression by interfering with the accessibility of genes to transcription factors 12 . Hence, methylation can profoundly affect transcription levels and an epigenetic mode of inheritance might significantly modify the effect of genotype upon phenotype.
Furthermore, methylation results from either directionally programmed changes, part of the ageing process, or from stochastic and spontaneous alterations attributed to environmental factors 13, 14 . It is difficult to predict, as of yet, the reason why and at which rate some nonage-associated CpG sites undergo changes in methylation. It is known that an individual's methylation profile may change in response to physical activity 23 . However, somewhat surprisingly, the role that DNA methylation plays, as an epigenetic factor, has never been investigated in relation to human tendinopathy. With this in mind, the aims of the present study were to establish, for the first time, whether epigenetics, in particular DNA methylation, was changed in tissue isolated from patellar tendinopathy compared to healthy tissue. Our study specifically focused on the DNA methylation statuses of the TIMP2 and ADAMTS4 genes in a targeted approach as both, as discussed above, undergo changes in expression during tendinopathy but the mechanisms underlying these changes are unknown.
Material and methods
Patellar tendon tissue was obtained from 10 male participants with healthy patellar tendons (CON) undergoing ACL reconstruction surgeries using a patellar tendon graft. We also were bisulfite treated using the EpiTect® fast DNA bisulphite Kit (Qiagen, Hilden, Germany)
according to the manufacturer's recommendation. The Pyrosequencing assays for the TIMP2 (Hs_TIMP2_01_PM) and ADAMTS4 (Hs_NDUFS_01_PM) genes used in this study were selected from the pre-designed PyroMark® CpG Assays (Qiagen, Hilden, Germany).
The single assay designed for the CpG island within the TIMP2 promoter region measured methylation at 4 CpG sites. (-488 bp, -478 bp, -467 bp, and -455 bp from the first exon). The assay chosen for the CpG sites within the promoter region of the ADAMTS4 gene was selected to cover a wider area of the promoter region and spanned 6 CpG sites that were -2964 bp, -2973 bp, -2995 bp, -2998 bp, -3000 bp and -3002 bp from the first exon. We took a pragmatic approach to the choice of CpG sites that we investigated. In some cases it was not possible to study certain regions of the promoters as sequencing assays did not meet quality control standards. However, as ADAMTS4 is regulated by a large promoter sequence 25 , we were especially interested to determine how methylation of CpG sites that are distant to the transition start site impacted on injury risk.
All bisulfite converted DNA samples in addition to hypermethylated and hypomethylated controls were PCR amplified using the pre-designed primer sets of the PyroMark® CpG figure 2 . In our cohort the CON and PT groups were similarly matched for age (p=0.449) and gender. For TIMP2 we found no significant difference (p=0.885) in the mean methylation percentages across all 4 sites between the CON and the PT groups.
Furthermore, there was no significant difference in methylation for any of the 4 CpG sites when analysed independently between the CON and the PT groups as shown in figure 3 .
However, for the ADAMTS4 gene, CpG site 3 was significantly (P=0.016) more methylated in the PT group compared to the CON group ( figure 3 ). Further data analysis showed no significant difference between CON and PT in the remaining 5 sites when analysed independently (figure 3), or for the mean percentages of methylation across the 6 sites (p=0.294).
Discussion
To our knowledge, this is the first study to investigate DNA methylation differences in clinically resected human tendinopathy samples compared to healthy tendon tissue. Unlike the recent study of Trella and co-workers 27 who used a genome wide design in a mouse tendinopathy study, we employed a hypothesis-driven, targeted approach to study methylation profiles of two genes (TIMP2 and ADAMTS4) that have been associated with the tendinopathic process in human 15, 20 .
TIMP2 is known to be under epigenetic control with a CpG island in the promoter region of the gene extending from the transcription initiation site upstream for approximately 900 bp 18 .
The methylation of the CpG sites located between positions -295 and -145 bp was found to reduce the expression of TIMP2 in prostate cancer samples 18 . Likewise, the overlapping region ranging from -350 to -240 bp was also found to be over-methylated in cervical cancer 28 . However, our work showed that there were no methylation changes within the CpG Island ranging from position -488 to -455 between the CON and PT tissue samples.
Moreover, all analysed samples showed very low methylation levels which might infer that this region of the TIMP2 promoter is not involved in regulating TIMP2 expression or deregulation during the process of patellar tendinopathy. Furthermore, the lack of change in TIMP2 methylation status between PT tissue and controls shown here is consistent with the absence of TIMP2 expression level changes between PT and control tissue previously shown by Parkinson et al (2010) 24 . The fact that we found no difference in TIMP2 methylation status between PT tissue and controls it interesting. This might suggest that previously observed differences in TIMP2 expression in Achilles tendinopathy 17 are not an active part of the tendinopathic process but possibly no more than an artefact of the injury.
Of course, we only interrogated a small number of CpG sites for TIMP2 in this study and investigating a larger area might well have revealed significant differences between the PT and CON samples.
Of the 6 CpG sites investigated 3 kb upstream of the ADAMTS4 gene we found one site, located at position -2995, that was significantly (p=0.016) more methylated in the PT group compared to the CON group. Although only one of the 6 CpG sites was more methylated in the tendinopathic tissue compared to controls, the impact of this when considering the risk of patellar tendinopathy might be far reaching. To be specific, the ADAMTS4 gene is known to be under epigenetic control 22 and regulated by a large promoter (-4109 to +406) that consists of two NFAT and several Runx binding elements 25 . One of the NFAT binding regions resides only 103 bp away from the CpG site that we investigated and it is plausible that a change in methylation status at that site, as measured by us, could affect the binding of NFAT transcription factors and alter the expression of ADAMTS4. Interestingly, an increase in the accumulation of proteoglycans including aggrecan was found previously in PT tissue taken from the participants in this study 24 and others 29 . However, somewhat surprisingly, ADAMTS4 levels in this patient cohort did not differ compared to controls 24 .
Recently, the expression of ADAMTS4 was shown to decrease, in a region specific manner, in an ovine model of tendinopathy Although our study was the first, to our knowledge, to report DNA methylation changes associated with human tendinopathy there were some limitations. Firstly, although our participants were all male with no significant age differences between the PT cases and controls we were unable to control for height, weight or level of physical activity in our dataset as this information was not available to us. The acquisition of such data in future experiments would improve confidence in the interpretation of the results. Secondly, our study was limited to a small number of clinical samples that were available from Caucasian men. Therefore, the changes we observed may not represent methylation changes that might occur in other populations. Hence, this work should be validated in larger, nonCaucasian cohorts and in female patients. Finally, this study has revealed that an overmethylation event in the promoter sequence of the ADAMTS4 gene associates with patellar tendinopathy. The hypermethylated CG site sits close to an important DNA regulatory element and might influence risk of tendinopathy by modifying ADAMTS4 levels leading to structural or regulatory changes within the ECM components of the tendon. Such changes might predispose an individual to develop the injury.
Conclusions
We provide the first evidence that DNA methylation (an epigenetic factor) within the promoter sequence of the human ADAMTS4 gene might be important in patellar tendinopathy. Our data have clear implications as set out below:
Practical implications
 As DNA methylation changes are modified by the environment it might be possible, in the future, to alter methylation status, through adaptions to an athlete's training programme, to reduce the risk of tendinopathy.
 DNA methylation changes might well explain discrepant gene association findings that have been observed in some studies on human tendinopathy.
 DNA methylation, as an epigenetic factor, should be considered as a potential modifier of genotype and other biochemical factors when considering risk of tendinopathy. 
